Product Center
Yisuda®Suraxavir Marboxil Tablets
Yisuda®Suraxavir Marboxil Tablets are a novel antiviral medication for the treatment of uncomplicated influenza A and B in previously healthy adolescents aged 12 and above, and adults.
Aurantii® Fructus Immaturus Total Flavonoids Tablet
Aurantii® Fructus Immaturus Total Flavonoids Tablet have good therapeutic effects on common symptoms of functional dyspepsia (such as liver-stomach disharmony, spleen-stomach damp-heat, food stagnation, and spleen-stomach deficiency).
Xiyanping Injection
Xiyanping Injection is a traditional Chinese medicine injection made from total sulfated andrographolide, a key component of Andrographis paniculata. It is part of the National “12th Five-Year Plan” Major Innovative Drug Discovery Project.
Qingruitan®Brivaracetam Tablets
Brivaracetam is an innovative third-generation antiepileptic drug that selectively targets synaptic vesicle protein 2A (SV2A) with high affinity.
Bangkaxin®Esomeprazole Magnesium Enteric-coated Tablets
Bangkaxin® Esomeprazole Magnesium Enteric-coated Tablets are a new generation of proton pump inhibitors (PPIs), approved as a Class 4 chemical drug. It is the only esomeprazole magnesium enteric-coated tablet in China that is bioequivalent to the original brand. It is clinically used for the prevention and treatment of acid-related diseases such as gastroesophageal reflux disease (GERD), peptic ulcers, stress ulcers, Helicobacter pylori eradication, and drug-induced gastric mucosal injury. It is widely used in clinical practice and is a first-line choice for acid suppression therapy and ulcer prevention and treatment.
Zebeining® Palbociclib Capsuless
Zebeining® Palbociclib Capsuless are an oral CDK4/6 inhibitor that selectively targets and inhibits the activity of the CDK4/6-Cyclin D1 complex. This prevents tumor cells from passing through the G1 to S phase checkpoint, blocking the cell cycle and inhibiting tumor cell proliferation.It is primarily used for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer, in combination with aromatase inhibitors as initial endocrine therapy for postmenopausal women.
Weiyiqing®Tenofovir Alafenamide Fumarate tablets
Tenofovir Alafenamide Fumarate (TAF) is an advanced nucleotide reverse transcriptase inhibitor that outperforms traditional Tenofovir Disoproxil Fumarate (TDF) with greater plasma stability and targeted delivery to the liver.
Weiliqing® Entecavir dispersible tablets / capsules
Weiliqing® Entecavir dispersible tablets / capsules is a nucleoside analogue used for antiviral treatment of chronic hepatitis B. It has many advantages, such as low resistance rates, strong antiviral activity, and the ability to significantly suppress HBV replication, making it highly effective for treating chronic hepatitis B in adults.
Qingketan® Tedizolid Phosphate Tablets
Qingketan® Tedizolid Phosphate Tablets are a second-generation oxazolidinone antibiotic, used to treat acute bacterial skin and soft tissue infections (ABSSSI) caused by the following Gram-positive bacteria: Staphylococcus aureus (including Methicillin-resistant Staphylococcus aureus [MRSA] and Methicillin-sensitive Staphylococcus aureus [MSSA] isolates), Streptococcus pyogenes, Enterococcus faecalis, Streptococcus anginosus group (including Streptococcus pyogenes, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecium.
Qingkesha® Posaconazole Injection
Qingkesha® Posaconazole Injection is a new-generation triazole antifungal drug, widely used in the prevention and treatment of invasive fungal diseases. It primarily works by inhibiting CYP450-dependent 14α-demethylase, which subsequently blocks the synthesis of ergosterol, leading to a disruption in the biosynthesis of the fungal cell membrane and altered cell membrane permeability, thereby inhibiting fungal growth.
Qingkesha® Posaconazole Enteric-coated Tablets
Qingkesha® Posaconazole Enteric-coated Tablets are a new-generation triazole antifungal drug, widely used for the prevention and treatment of invasive fungal diseases. Like the injection formulation, it works by inhibiting CYP450-dependent 14α-demethylase, blocking the synthesis of ergosterol, and disrupting the fungal cell membrane biosynthesis, altering its permeability and inhibiting fungal growth.
Hailixin® Quassia Injection
Hailixin® Quassia Injection is a single-ingredient modern traditional Chinese medicine injection with broad-spectrum antibacterial, potent antiviral, and more effective antipyretic clinical actions. It is widely used in the treatment of respiratory diseases such as the common cold, upper respiratory tract infections, acute tonsillitis, purulent tonsillitis, herpetic pharyngitis, and bronchial pneumonia, as well as intestinal diseases like enteritis, mesenteric lymphadenitis, and dysentery. Currently, the product is used in nearly 300,000 primary healthcare institutions and has become a commonly used medication for respiratory and intestinal diseases at the grassroots level.
Qingketan® Tedizolid Phosphate for Injection
Qingketan® Tedizolid Phosphate for Injection is a second-generation oxazolidinone antibiotic, used to treat acute bacterial skin and soft tissue infections (ABSSSI) caused by the following Gram-positive bacteria: Staphylococcus aureus (including Methicillin-resistant Staphylococcus aureus [MRSA] and Methicillin-sensitive Staphylococcus aureus [MSSA] isolates), Streptococcus pyogenes, Enterococcus faecalis, Streptococcus anginosus group (including Streptococcus pyogenes, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecium.
Xinzhuo® Afatinib Dimaleate Tablets
Xinzhuo® Afatinib Dimaleate Tablets are the first irreversible ErbB family receptor blockers. They covalently bind to the kinase regions of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4), irreversibly inhibiting tyrosine kinase autophosphorylation, leading to downregulation of ErbB signaling and inhibiting tumor cell proliferation. Xinchuo® was approved for market in August 2021 and is indicated for: Locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR gene-sensitive mutations in patients who have not previously received EGFR tyrosine kinase inhibitors (TKI) treatment. Locally advanced or metastatic squamous cell carcinoma of non-small cell lung cancer (NSCLC) with disease progression during or after platinum-based chemotherapy.
